Nuria Martinez Velasco
Investigador pre-doc
Research group
Nuria Martínez graduated in Pharmacy in 2022 from San Jorge University.
She is currently a doctoral student in Drug Research, Development, and Control at the University of Barcelona.
Professional network profiles
Last Publications
- Balaguer-Lluna L, Resa-Parés C, Brstilo L, Gómez-Caballero A, Baulenas-Farrés M, Mohr J, Hu Y, Aschero MR, Rodríguez A, Botteri G, Rodriguez E, Li-Chen L, Mañogil R, Marino F, Martinez N, Ruano A, García-Pelayo Á, Giron A, Mora J, Lavarino C, Sánchez-Navarro M, Teixidó M, Ormazabal-Herrero A, Artuch-Iriberri R, Unceta N, Schaiquevich P and Carcaboso AM CNS distribution and preclinical activity of the PI3K/AKT inhibitors inavolisib and ipatasertib in pediatric-type diffuse high-grade gliomas. CANCER CHEMOTHERAPY AND PHARMACOLOGY . 96(1): .
- Lomba, L, Polo, A, Martinez N, Alejandre, J and Giner, B Solubility and Stability of Carvedilol in Deep Eutectic Solvents: A Step Towards a Sustainable Pharmaceutical Formulation in the Liquid State ChemistrySelect . 9(11): .
- Pascual-Pastó G, Resa-Parés C, Castillo H, Aschero MR, Baulenas-Farrés M, Vilà-Ubach M, Burgeño-Sandoval V, Balaguer-Lluna L, Cuadrado-Vilanova M, Gene-Olaciregui N, Martinez N, Pérez-Jaume S, de Alava, E, Tirado, OM, Lavarino C, Mora J and Carcaboso AM Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma. BIOCHEMICAL PHARMACOLOGY . 208: 115408-115408.
Projects
- Project name:
- Formación de doctores del programa nacional de formación de profesorado universitario 2022. Beneficiari: Núria Martínez
- Leader
- Angel Montero Carcaboso
- Funding entities:
- Ministerio De Universidades
- Code
- FPU22/00395
- Starting - finishing date:
- 2023 - 2027
- Project name:
- Brain-penetrant medicines for diffuse infiltrative pediatric gliomas
- Leader
- Angel Montero Carcaboso
- Funding entities:
- Clientes Diversos
- Code
- PFNR0169
- Starting - finishing date:
- 2022 - 3000
News
-
Researchers at IRSJD develop a method to predict the efficacy of a potent nanomedicine in a severe childhood cancer
Researchers at IRSJD have developed a method that predicts the anticancer efficacy of nab-paclitaxel, a well-known nanomedicine, in mouse models, for treatment of Ewing sarcoma, a severe cancer affecting the bones and soft tissue of children and adolescents.
